ALS (motor neurone disease): who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• TDP-43 8
• SOD1 7
• C9orf72 4
• NRF2 0
• STING 0
• SIRT1 0
• HDAC 0
• NLRP3 0
• TREM2 0
• BDNF 0
• MAPK 0
• APOE 0
• GLP-1 0
• HMGB1 0
• mTOR 0
• SMN1 0
• TP53 0
• AMPK 0
• BTK 1
• CXCR4 0
• HSP90 1
• JAK 0
• JNK 0
• LAG-3 0
• NMDA 0
• PI3K 0
• PINK1 0
• PPAR 0
• TFEB 0
• TNF 0
• AKT 0
• APP 0
• ATM 0
• AXL 0
• BCL-2 0
• CDK4/6 0
• COX-2 0
• CSF1R 0
• ERK 0
• GPX4 0
• IL-1 0
• MAPT 0
• PARP 0
• PCSK9 0
• PDE4 1
• PSEN1 0
• PTEN 0
• SNCA 0
• STK11 0
• TLR4 0
• TTR 0
• VEGF 0
• YAP 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 1,181 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intrathecal Injection for ALS

  NCT05003921· The Foundation for Orthopaedics and Regenerative Medicine· Updated 16 Oct 2026

  “Inability to recruit patients”Registry text, quoted unchanged. Source

• Suspended

  A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

  NCT04031469· ProgenaBiome· Updated 21 Sept 2026

  “Administrative”Registry text, quoted unchanged. Source

• Withdrawn

  Evaluation of the Early Use of the Pressure Relaxer in the Respiratory Impairment of Patients With Amyotrophic Lateral Sclerosis: Multicenter Randomized Controlled Study.

  NCT05297487· Centre Hospitalier Universitaire de la Réunion· Updated 16 Sept 2026

  “lack of human ressources”Registry text, quoted unchanged. Source

• Terminated

  Amyotrophic Lateral Sclerosis Non-invasive Ventilation Exchange

  NCT05837507· University Hospital, Montpellier· Updated 16 Jun 2026

  “lack of recruitement”Registry text, quoted unchanged. Source

• Withdrawn

  IC14 for Treatment of Amyotrophic Lateral Sclerosis

  NCT03508453· Implicit Bioscience· Updated 5 May 2026

  “No participants enrolled in study”Registry text, quoted unchanged. Source

• Withdrawn

  Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis

  NCT02988297· Revalesio Corporation· Updated 16 Apr 2026

  “Withdrawn prior to initiation”Registry text, quoted unchanged. Source

• Terminated

  Satisfaction of Patients With Amyotrophic Lateral Sclerosis Regarding Home Assisted Teleconsultation

  NCT05621213· AGIR à Dom· Updated 6 Feb 2026

  “The study was terminated early due to insufficient recruitment despite mitigation measures, as enrolment rates could not meet protocol objectives. Academic thesis scheduling constraints also contributed. No safety concerns were identified.”Registry text, quoted unchanged. Source

• Terminated

  Continuation Study for Latozinemab

  NCT06111014· Alector Inc.· Updated 21 Jan 2026

  “The AL001-CS-302 study was terminated because its Phase 3 placebo-controlled parent study (AL001-3) failed to meet the clinical co-primary endpoint of slowing FTD-GRN progression, as measured by the Clinical Dementia Rating® plus National Alzheimer's”Registry text, quoted unchanged. Source

• Suspended

  Atalante Exoskeleton in the Rehabilitation of Patients With Amyotrophic Lateral Sclerosis

  NCT06199284· Institut de Recherche sur la Moelle épinière et l'Encéphale· Updated 12 Jan 2026

  “Recruitment is suspended due to funding issues”Registry text, quoted unchanged. Source

• Terminated

  A Study of STRO4 in Patients Amyotrophic Lateral Sclerosis (ALS)

  NCT06910384· New England Cell Therapeutics, Inc.· Updated 18 Dec 2025

  “organizational restructure”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms

  NCT04856982· Biogen· Source

• A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic Lateral Sclerosis (ALS)

  NCT07855211· Biogen· Source

• Brain-Computer Interface Communication Device for People With ALS

  NCT07871071· Cognixion· Source

• Ultra-high-caloric, Fatty Diet in ALS

  NCT06280079· University of Ulm· Source

• Do Video Recordings of Multidisciplinary Clinics Improve Quality of Life for People With ALS and Their Caregivers?

  NCT07454733· Trustees of Dartmouth College· Source

• ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

  NCT04363684· Mayo Clinic· Source

• A Study to Evaluate, Safety, Tolerability, and PK of AP-101 in Participants With ALS

  NCT05039099· AL-S Pharma· Source

• Developing New Ways to Detect Respiratory Impairment Early in ALS

  NCT07844590· Thomas Jefferson University· Source

• A Randomized Phase 1 / 2 Trial Aiming to Restore UNC13A Function in People living with ALS: FUNCtion ALS

  2025-523111-11-00· Trace Neuroscience Inc.· Source

• 7T Imaging Pilot-study in Patients With Motor Neuron Disease to Find Non-Invasive Disease Imaging Biomarkers

  NCT07818772· NHS Greater Glasgow and Clyde· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 7
• Organoids 7
• Mendelian Randomization Analysis 18
• CRISPR-Cas Systems 8
• Gene Expression Profiling 23
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 6
• Exome Sequencing 6
• Proteomics 29
• Metabolomics 7
• Mass Spectrometry 6
• Flow Cytometry 2
• Immunohistochemistry 5
• Liquid Biopsy 2
• Positron-Emission Tomography 13
• Magnetic Resonance Imaging 57
• Machine Learning 18
• Deep Learning 7
• Cohort Studies 79
• Genome-Wide Association Study 24

• Cerebrospinal fluid inflammatory proteomic profiling identifies biomarkers linked to disease progression in amyotrophic lateral sclerosis.

  J Neurol, Oct 2026

• Plasma Proteomic Signatures Predict Incident Amyotrophic Lateral Sclerosis: A Prospective Study Stratified by C9orf72 Expansion.

  J Cachexia Sarcopenia Muscle, Oct 2026

• Integrative synaptosome multi-omics reveals disrupted synapse organization and localized cryptic transcripts in C9ORF72-frontotemporal dementia.

  Acta Neuropathol, Sept 2026

• Proteomic and Functional Signatures of Phenoconversion in Presymptomatic Amyotrophic Lateral Sclerosis.

  J Clin Neuromuscul Dis, Sept 2026

• In-Vitro Evaluation of HIV/SARS-CoV-2 Co-Infection Mediated Proteomic Changes in Astrocytes and Pericytes Reveals Altered Signaling Pathways Associated With Neurodegenerative Disorders.

  J Med Virol, Aug 2026

• Longitudinal plasma proteomics predict phenoconversion to clinically manifest ALS.

  Nat Med, Jul 2026

• Proteome-wide Mendelian randomization identifies causal plasma proteins in frontotemporal dementia.

  Neurol Sci, Jul 2026

• Cross-disease LC-MS/MS plasma proteomics identifies reproducible shared and disease-enriched biomarker signatures in neurodegenerative disorders.

  Acta Neuropathol Commun, Jul 2026

• Plasma proteomic signatures of cellular aging predict human disease.

  Nat Med, Jun 2026

• Quantitative Proteomics Unveils Comprehensive Tissue-Specific VCP Interaction Networks in Mice.

  Sci Data, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.